| Treatment | Total costs | Total QALYs | ICER |
|---|---|---|---|
| FEV1% utility | |||
| Nebulised colistimethate sodium | £107,149 | 12.99 | - |
| Nebulised tobramycin | £244,890 | 13.10 | £1,226,546 |
| Tinnitus excluded | |||
| Nebulised colistimethate sodium | £125,002 | 11.35 | - |
| Nebulised tobramycin | £205,664 | 11.54 | £416,476 |
| Within-trial analysis | |||
| Nebulised colistimethate sodium | £4,421 | 0.42 | - |
| Nebulised tobramycin | £8,417 | 0.42 | £1,524,290 |
| Hodson 2002 (FEV1%) | |||
| Nebulised colistimethate sodium | £107,149 | 11.35 | - |
| Nebulised tobramycin | £245,239 | 11.48 | £1,023,402 |
| Hodson 2002 (cost) | |||
| Nebulised colistimethate sodium | £107,149 | 11.35 | - |
| Nebulised tobramycin | £308,804 | 11.58 | £882,028 |
| Nebulised colistimethate sodium cost | |||
| Nebulised colistimethate sodium | £147,748 | 11.35 | - |
| Nebulised tobramycin | £244,890 | 11.58 | £424,896 |
| Nebulised tobramycin drug cost | |||
| Nebulised colistimethate sodium | £107,149 | 11.35 | - |
| Nebulised tobramycin | £251,416 | 11.58 | £631,016 |
| Nebulised colistimethate sodium dose | |||
| Nebulised colistimethate sodium | £125,002 | 11.35 | - |
| Nebulised tobramycin | £244,890 | 11.58 | £524,384 |
| WinBUGS | |||
| Nebulised colistimethate sodium | £107,568 | 11.34 | |
| Nebulised tobramycin | £245,306 | 11.57 | £602,328 |
| PAS | |||
| Nebulised colistimethate sodium | No change | 11.35 | - |
| Nebulised tobramycin | Reduced | 11.58 | Reduced (>£30,000) |
FEV, forced expiratory volume; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; PAS, patient access scheme; SA, sensitivity analysis
From: Appendix K, Health Economics
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.